- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01282697
Clinical Trial of Rapamycin and Irinotecan in Pediatric Patients With Refractory Solid Tumors (RAPIRI)
December 6, 2019 updated by: University Hospital, Strasbourg, France
Phase I Clinical Trial of Rapamycin and Irinotecan in Pediatric Patients With Refractory Solid Tumors
Therapeutic solutions to treat solid tumors that are resistant to conventional treatments are now limited.
Laboratory data in animals (on pediatric tumors such as brain tumors, sarcomas and neuroblastomas) have shown that the combination of irinotecan (HIF1alpha inhibitor) and rapamycin (mTOR inhibitor) allowed to block development of blood vessels in the tumor and could, in some cases, stop its progression.
This drug combination has already been tested in adult patients with refractory tumors and seems to give encouraging results with stabilization of the tumor.
The dose and toxicity of irinotecan and rapamycin are known when these drugs are administered separately and in a context different from that of refractory tumors.
RAPIRI is a phase I clinical trial whose principal objectives are to determine the maximum dose at which these two molecules may be administered and to assess the safety of this new combination of drugs.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
42
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bordeaux, France, 33076
- Hôpital des Enfants - Groupe Hospitalier Pellegrin
-
Lille, France, 59020
- Centre Oscar Lambret
-
Lyon, France, 67008
- Institut Hémato-Oncologie Pédiatrique (IHOP)
-
Marseille, France, 13005
- CHU La Timone
-
Nantes, France, 44093
- CHU Mère-Enfants
-
Paris, France, 75005
- Institut Curie
-
Strasbourg, France, 67098
- Hôpitaux Universitaires de Strasbourg
-
Toulouse, France, 31059
- Hôpital Des Enfants
-
Villejuif, France, 94805
- Institut Gustave Roussy
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 year to 21 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age >= 1 year old and =< 21 years old;
- Refractory solid tumors, histologically proven at diagnosis (no additional biopsy needs to be performed for the purpose of the study);
- Relapsed or refractory solid tumors after standard treatment or phase II, III-IV clinical trials treatment have failed;
- Karnofsky or Lansky status >= 70%;
- Life expectancy >= 8 weeks;
- No chemotherapy / radiotherapy within 4 weeks before entry into the study;
Adequate biological parameters :
- Absolute neutrophil count >= 1.0 x 109/L;
- Platelet count >= 100 x 109/L;
- Hemoglobin >= 8 mg/dL;
- Total bilirubine =< 1.5 ULN;
- Transaminases =< 2.5 ULN (=< 5 ULN in case of liver metastases);
- Creatinine clearance (Cockroft) >= 70 mL/min/1.73 m2;
- Normal coagulation profile with prothrombin >= 70%, TCA =< 35 and fibrinogen >= 2 g/L;
- Patients with 1 to 3 previous therapeutic lines are eligible;
- No current grade >= 2 organ toxicity based on NCI-CTCAE version 3.0;
- All patients with reproductive potential must have an effective method of birth control while on study;
- Negative pregnancy test in females when indicated;
- Informed written consent signed by patients or their parents or legal guardians;
- Patient who was informed of the results of prior medical consultation;
- Patient having a social insurance.
Exclusion Criteria:
- Patient with a constitutional anomaly of coagulation and/or of hemostasis (type hemophilia, von Willebrand disease, congenital clotting factor deficit, platelet disorder), exposing them to increased risk of bleeding;
- Pre-treatment with a mTOR inhibitor;
- Other simultaneous malignancy;
- Concurrent administration of any other anti-tumour therapy;
- Known hypersensitivity or contraindication to study drugs or ingredients;
- Severe concomitant disease (e.g. infection disease);
- Patient unable for medical follow-up;
- Pregnancy and/or lactation;
- Patient included in another clinical drug trial;
- Patient taking drugs interfering with pharmacology of rapamycin and/or irinotecan (e.g. drugs interfering with CYP3A4);
- Patient under judicial protection.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: rapamycin+irinotecan at a given dose
|
This phase I trial is a dose escalation study of irinotecan + rapamycin with a 3+3 statistical design.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determine the maximum tolerated dose (MTD) of irinotecan and rapamycin combination in children with refractory solid tumors.
Time Frame: 28 days
|
The Dose-Limiting Toxicity (DLT) of the drug combination is determined during the first cycle (J1 to J28) of treatment.
MTD will be defined as the dose level immediately below the dose level at which 2 patients in a cohort of 3 to 6 patients will have experienced a DLT.
|
28 days
|
Characterize the pharmacokinetics of rapamycin and irinotecan during the first cycle of treatment.
Time Frame: Day1 + day8
|
Pharmacokinetic parameters for rapamycin will be evaluated at days 1 and 8 of the first cycle of treatment.
Pharmacokinetic parameters for irinotecan will be evaluated at day 1 of the first cycle of treatment.
Pharmacokinetic profile will be modelized for each patient.
|
Day1 + day8
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Natacha ENTZ-WERLE, MD, PhD, Hôpitaux Universitaires de Strasbourg
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 22, 2011
Primary Completion (Actual)
February 20, 2013
Study Completion (Actual)
February 20, 2013
Study Registration Dates
First Submitted
November 12, 2010
First Submitted That Met QC Criteria
January 24, 2011
First Posted (Estimate)
January 25, 2011
Study Record Updates
Last Update Posted (Actual)
December 9, 2019
Last Update Submitted That Met QC Criteria
December 6, 2019
Last Verified
December 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Topoisomerase Inhibitors
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Antifungal Agents
- Topoisomerase I Inhibitors
- Irinotecan
- Sirolimus
Other Study ID Numbers
- 4791
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Refractory Solid Tumors in Children
-
Children's Hospital Los AngelesCompleted
-
University of Colorado, DenverUniversity of KentuckyCompletedRefractory Solid Tumors | Relapsed Solid TumorsUnited States
-
Gustave Roussy, Cancer Campus, Grand ParisUnknown
-
Cancer Institute and Hospital, Chinese Academy...RecruitingRefractory Solid Tumors | Relapsed Solid TumorsChina
-
National Cancer Institute (NCI)RecruitingSolid Tumor | Refractory Solid Tumors | Malignant Solid Tumors | Other Neoplasms Solid Tumors | Pediatric Solid TumorUnited States
-
Samsung Medical CenterCompletedRefractory Solid TumorsKorea, Republic of
-
Samsung Medical CenterCompletedRefractory Solid TumorsKorea, Republic of
-
Samsung Medical CenterCompletedRefractory Solid TumorsKorea, Republic of
-
TCRx Therapeutics Co.LtdRecruitingRefractory Solid Tumors | Relapsed Solid Tumors | TCR-T CellsChina
-
M.D. Anderson Cancer CenterRecruitingRefractory Solid TumorsUnited States
Clinical Trials on Combined administration of irinotecan and rapamycin
-
CSPC Ouyi Pharmaceutical Co., Ltd.UnknownAdvanced Pancreatic CancerChina
-
Zhejiang Cancer HospitalNot yet recruitingAdvanced Colorectal CancerChina
-
Nanfang Hospital of Southern Medical UniversityRecruiting
-
Peking UniversityCompletedProgression Free Survival of the TreatmentChina
-
University of Southern CaliforniaNational Cancer Institute (NCI); IpsenWithdrawnGastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Unresectable Gastroesophageal Junction Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Locally Advanced Unresectable Gastric Adenocarcinoma | Metastatic Unresectable Gastric AdenocarcinomaUnited States
-
Tianjin Medical University Cancer Institute and...Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Not yet recruitingRefractory or Recurrent Neuroblastoma in Children
-
Technical University of MunichUnknownRecurrent Ewing Sarcoma | Recurrent Rhabdomyosarcoma | Recurrent Childhood Soft Tissue Sarcoma
-
Shanghai Zhongshan HospitalRecruitingColorectal Neoplasms MalignantChina
-
First People's Hospital of HangzhouRecruitingRelapsed Small Cell Lung Cancer | AnlotinibChina
-
Fudan UniversityUnknownRecurrent Colorectal CancerChina